Is a Twice Daily Dosage of Isosorbide-5-Mononitrate Sufficient in the Treatment of Stable Angina Pectoris?

  • O. J. Luurila
  • R. Kala
  • P. Hirvonen
  • A. Kohvakka
  • S. Sundberg
  • K. Lukkala
Part of the International Boehringer Mannheim Symposia book series (BOEHRINGER)

Abstract

Isosorbide-5-mononitrate (IS-5-MN) is the long-acting metabolite of isosorbide dinitrate. Oral IS-5-MN does not undergo first-pass metabolism and its bioavailability is almost 100%, which makes administration easier and more predictable [1]. It has been shown to exert antianginal effects both on acute and chronicc administration [2–4].

Keywords

Placebo Fatigue Depression Creatinine Nitroglycerin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abshagen U (1985) Pharmacokinetics of ISDN, sustained release ISDN and IS-5-MN. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer-Verlag, Berlin Heidelberg New York, pp 53–66CrossRefGoogle Scholar
  2. 2.
    Müller G, Überbacher HJ, Glocke M (1985) Double-blind, randomized cross-over study on the coronary therapeutic efficacy and tolerance of IS-5-MN (ISMO 20) in a comparison with IS-5-MN + Metipranolol (ISMO-Disorat 20/5) and placebo. In: Cohn JN, Rittinghausen R (eds). Mononitrates. Springer-Verlag, Berlin Heidelberg New York, pp 221–229CrossRefGoogle Scholar
  3. 3.
    Schiavoni G, Montenero AF, Mazzari M, Biasucci LM and Manzoli U (1985) The efficacy of IS-5-MN in patients with ischemic heart disease: A pilot study. In: Mononitrates, International Boehringer Mannheim Symposia, eds. Cohn JN, Rittinghausen R, Montreaux, Switzerland, 230–234CrossRefGoogle Scholar
  4. 4.
    Rennhak U, Riebesel T and Biamino G (1985) A Double-Blind Cross-Over Study on the Effectiveness and Possible Development of Tolerance during Long-Term Therapy with Isosor-bide-5-Mononitrate or Isosorbide Dinitrate Slow-Release in Coronary Artery Disease. In: Mononitrates, International Boehringer Mannheim Symposia, eds. Cohn JN and Rittinghausen R, Montreaux, Switzerland, 147–153CrossRefGoogle Scholar
  5. 5.
    Parker JO (1985) Nitrate tolerance. Am J Cardiol 65: 281–311Google Scholar
  6. 6.
    Silber S, Krause KH, Theisen K and Jahrmärker H (1985) Nitrate tolerance: do “critical” plasma levels exist? Circulation II, 7: III-431 (1724)Google Scholar
  7. 7.
    Ohlmeier H, Mertens HM, Mannebach H and Gleichmann U (1985) Tolerance and Rebound Phenomena in Nitrate Therapy. In: Mononitrates, International Boehringer Mannheim Symposia, Eds. Cohn JN, Rittinghausen R, Montreaux, Switzerland, 107–123CrossRefGoogle Scholar
  8. 8.
    Jansen W, Tauchert M, Osterspey A and Hilger HH (1985) Comparison of the Hemodynamic Effects of Various Doses of Isosorbide-5-Mononitrate Following Single-Dose and Long-Term Administration in Patients with Coronary Heart Disease. In: Mononitrates, International Boehringer Mannheim Symposia, eds. Cohn JN, Rittinghausen R, Montreaux, Switzerland, 171–187CrossRefGoogle Scholar
  9. 9.
    Rudolph W, Blasini R, Reiniger G and Brügmann U (1983) Tolerance development during isosorbide dinitrate treatment: Can it be circumvented? Z Kardiol 72, Suppl 3, 195–198PubMedGoogle Scholar
  10. 10.
    Kala R, Hirvonen P, Gordin A, Sundberg S, Auvinen J and Halonen PI (1983) Nitroglycerin ointment effective for seven hours in severe angina pectoris. Acta Med Scand 213: 165–170PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • O. J. Luurila
  • R. Kala
  • P. Hirvonen
  • A. Kohvakka
  • S. Sundberg
  • K. Lukkala

There are no affiliations available

Personalised recommendations